Dapagliflozin in combination with metformin was reported to be more cost-effective than a sulphonylurea or dipeptidyl-peptidase-4 inhibitor (DPP4i), when added to metformin in T2DM patients inadequately controlled on metformin alone in Greece33. Here, DPP4 is linked to type 2 diabetes mellitus.